Back to Search
Start Over
Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
- Source :
- Business Wire. August 31, 2021
- Publication Year :
- 2021
-
Abstract
- Elinzanetant is a non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause WHIPPANY, N.J. -- Bayer, a global leader in women's healthcare, announced today that it started [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.673777273